Speaker's Highlight

  • Don Sin University of British Columbia, St. Paul Hospital (Canada)
    Kenneth R. Chapman Toronto General Hospital Research Institute (Canada)
  • Parameswaran Nair McMaster University (Canada)
    Carolyn Calfee UCSF (U.S.A.)
  • Gregory P. Downey University of Colorado School of Medicine (U.S.A.)
    David A. Schwartz University of Colorado School of Medicine (U.S.A.)
  • Neil Schluger Tuberculosis Control Branch, California Department of Public Health (U.S.A.)
    Nick Kim Critical Care & Sleep Medicine, University of California San Diego (U.S.A.)
  • Nicola Hananiah Baylor College of Medicine (U.S.A.)
    Jae-Joon Yim Seoul National University College of Medicine (Republic of Korea)
  • Koichiro Asano Tokai University School of Medicine (Japan)
    Diahn-Warng Perng Taipei Veterans General Hospital (Taiwan)
  • Konstantinos Kostikas University of Ioannina (Greece)
    Karin Klooster University Medical Center Groningen (Kingdom of the Netherlands)
  • Pulmonary nocardiosis: when a chest infection resists the usual rules

    Pulmonary nocardiosis is an uncommon but important opportunistic lung infection caused by aerobic, branching filamentous bacteria of the genus Nocardia. It can resemble tuberculosis, fungal pneumonia or a routine bacterial chest infection, yet delayed recognition may allow cavitation, empyema or spread to the brain. The diagnostic challenge is usually a failure to connect the organism with the right clinical clues rather than a lack of distinctive symptoms.

    Most patients have impaired host defence because of COPD, bronchiectasis, diabetes, malignancy, corticosteroid treatment, transplantation or other immunosuppression. Presentation may be subacute, with fever, cough, sputum, dyspnoea, weight loss and haemoptysis, but severe disease can evolve quickly. People without an obvious risk factor can also be affected, so the absence of immunosuppression should not end suspicion.

    For clinicians attending APSR 2022 and those working in Australia, a practical approach combines host risk, CT findings, correctly collected specimens and early microbiology liaison. The aim is to recognise a treatable infection, distinguish disease from respiratory colonisation and ensure that any isolate reaches identification and antimicrobial susceptibility testing.

    Why the diagnosis is often delayed

    Nocardia is found in soil and enters through inhalation or, less commonly, skin inoculation. Organisms may be sparse in pulmonary specimens and obscured by neutrophils. A routine sputum Gram stain can fail to reveal the characteristic branching filaments, while a single negative respiratory culture does not exclude infection. This is why the clinical context and specimen-handling plan matter.

    Feature Pulmonary nocardiosis Tuberculosis Pulmonary aspergillosis
    Common context Structural lung disease or immunosuppression Exposure risk in any host Structural lung disease, transplantation or prolonged neutropenia
    CT pattern Nodules, consolidation, cavitation or pleural disease Cavitation, consolidation and tree-in-bud opacities Nodules or mass-like lesions around a cavity
    Laboratory clue Branching gram-positive filaments that may be weakly acid-fast Acid-fast bacilli Septate fungal hyphae with Aspergillus culture or other supporting tests
    Key action Request Nocardia-aware culture and retain the isolate Notify public health and pursue confirmatory testing Assess immune status and fungal investigations urgently

    These comparisons are useful but imperfect. Tuberculosis may have similar cavitation and constitutional symptoms, while pulmonary aspergillosis often centres on a pre-existing cavity; neither pattern reliably identifies Nocardia. “Chest infection” is a common phrase in Australian consultations, but it can group pneumonia, bronchitis and worsening COPD together. Ask specifically about blood in sputum, night sweats, headache, focal weakness and weight loss rather than relying on that shorthand.

    Clues that narrow the differential

    On CT, pulmonary nocardiosis may produce nodules, consolidation, cavitation, tree-in-bud opacities, pleural effusion or a mass-like lesion. Findings can be unilateral or multifocal and are not diagnostically specific. Comparison with previous scans can reveal progression despite apparently adequate treatment for ordinary bacterial pneumonia, particularly in someone with structural lung disease.

    Examination should document focal crackles, reduced air entry, fever and oxygen saturation while checking for signs of dissemination. Skin abscesses, unexplained nodules or lesions may provide another site for diagnosis. Headache, vomiting, confusion, seizures or focal neurological signs should not be attributed casually to infection; together with pulmonary disease, they raise concern for a nocardial brain abscess.

    An exposure history may include gardening, farming, excavation, recurrent corticosteroid use or biologic therapy. Darwin, Cairns and northern Queensland are relevant settings to ask about because outdoor soil exposure is common. Nocardia is not a tropical-exclusive pathogen, however, and cases occur throughout Australia.

    Getting a reliable laboratory diagnosis

    Specimen quality and communication with the laboratory are critical. When possible, obtain good-quality sputum, tracheal aspirate or bronchoalveolar lavage according to the clinical situation, and collect blood cultures if the patient is febrile or unstable. Tell microbiology that Nocardia is suspected so the specimen receives appropriate handling and incubation. The laboratory should also retain any isolate for further work.

    Microscopy may reveal thin, branching, gram-positive organisms that are weakly acid-fast with a modified stain, but sensitivity is variable. Culture remains central, with identification by MALDI-TOF mass spectrometry, validated biochemical methods or 16S rRNA sequencing. Neither a negative Gram stain nor a negative modified acid-fast smear can rule out nocardiosis, especially after antibiotics have begun.

    Antimicrobial susceptibility testing is essential because resistance patterns differ among Nocardia species and change over time. Ask whether the laboratory has an isolate-based method, needs an isolate to be sent to a reference laboratory, or can arrange testing through a specialist centre. In Australia, state and private hospital microbiology services may use different platforms and referral pathways, so respiratory and infectious diseases teams can help coordinate this process without delaying treatment.

    Treatment access and Australian practice

    No single antibiotic covers every isolate. Trimethoprim-sulfamethoxazole, commonly known in Australia as Bactrim or Septrin, is often active and is used for pulmonary disease. Severe infection may require combination therapy selected with specialist advice. Imipenem, amikacin, linezolid and other agents may be used according to species, susceptibility, disease site and toxicity. Central nervous system involvement requires particular attention to drug penetration and treatment duration.

    Medicare, the Pharmaceutical Benefits Scheme and public hospital formularies shape access. A stable patient may obtain subsidised oral treatment through a GP or specialist prescription, while inpatient options depend on hospital availability and antimicrobial stewardship. Because intravenous treatment, toxicities and prolonged courses can complicate outpatient care, coordinated respiratory and infectious diseases input is valuable in severe, recurrent or resistant disease.

    Rural and remote patients may begin in a local hospital or through telehealth, with samples travelling to a metropolitan laboratory and transfer needed for bronchoscopy or complex care. Aboriginal and Torres Strait Islander communities should be supported through local health services, transport assistance and culturally safe review, because distance, transport barriers and crowded housing can otherwise delay care. Nocardiosis is not routinely notifiable nationally, but suspected tuberculosis or mycobacterial disease must be managed through the appropriate notification pathway.

    From pulmonary disease to a coordinated next step

    Disseminated nocardiosis often involves the central nervous system, and pulmonary disease can coexist with brain abscess, skin lesions or, less commonly, endocarditis. Neurological symptoms in a patient with confirmed or suspected pulmonary nocardiosis warrant urgent contrast-enhanced MRI and prompt infectious diseases review. Blood cultures can be negative in localised disease, so a negative set should not provide false reassurance.

    Management should bring together respiratory review, infectious diseases advice, microbiology, imaging and pharmacy. Record the suspected diagnosis in referrals, avoid unnecessary delays, and monitor renal function, blood counts, electrolytes and drug-specific adverse effects. Radiographic improvement can support the diagnosis, but it cannot alone exclude a non-infectious mimic.

    For a stable outpatient with compatible findings, the immediate next step is to telephone the respiratory or infectious diseases team and microbiology laboratory that day to arrange Nocardia-aware specimen handling, isolate retention and susceptibility testing before antibiotics, when this can be done safely.

    Richard Russell Nuffield Department of Clinical Medicine, University of Oxford (United Kingdom)
  • Mona Bafadhel King’s College London (United Kingdom)
    David Jackson Guy’s and St Thomas’ Hospital, King’s College London (United Kingdom)
  • James Chalmers University of Dundee (United Kingdom)
    David Price University of Aberdeen (United Kingdom)

Copyright ⓒ APSR2022 all rights reserved

APSR Congress Privacy Policy